Overview
News
Salaries
Products
People
Growth
Offices
Financials

Overview

Tubulis is now part of Gilead Sciences. Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026.

News

News MedCity News 5 months ago
Gilead's Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis
Gilead Sciences' Tubulis acquisition brings antibody drug conjugates in clinical development for cancer. Analysts say the Tubulis platform technologies that yielded these ADCs could also help Gilead develop drugs in other therapeutic areas.
Read more
Report
News YahooFinance 8 months ago
Tubulis Unveils Alco5 Conjugation Platform's Ability to Expand ADC Payload Scope in Nature Communications
MUNICH, January 21, 2026--Tubulis today announced the publication of preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The paper describes the company's novel antibody-drug conjugate (ADC) technology and
Read more
Report
News Pulse 2.0 11 months ago
Tubulis: €308 Million Series C Secured To Advance Clinical Development Of Lead ADC Candidate TUB-040
Tubulis announced the closing of a €308 million ($361 million) Series C financing round aimed at accelerating the clinical development of its lead antibody-drug conjugate (ADC) candidate, TUB-040. The round was led by Venrock Healthcare Capital Partners a
Read more
Report
News STAT 11 months ago
German biotech Tubulis raises $358 million to advance cancer treatments
The company, which is developing antibody-drug conjugates, will use the funding to push its lead drug candidate into trials in additional types of cancer.
Read more
Report
News pharmaphorum 2 years ago
Gilead looks beyond Trodelvy with Tubulis alliance
Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m
Read more
Report
Pro access
Upgrade to see all 8 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.

Financials

Total raised
$561M
Latest round
Series C
Funding rounds
3
Funding rounds
Round Announced Amount
Series C 2025 $358M Details
Venture - Series Unknown 2024 $138.2M Details
Series B 2022 $64.8M Details